Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Erlotinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 23 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
- 21 Apr 2008 The expected completion date for this trial is now 1 Nov 2002.
- 17 Aug 2005 New trial record.